Important Announcements

ACL Laboratories continuously strives to provide the best laboratory services possible. Our Test Bulletins and Important Announcements include information regarding new test offerings, changes in test procedures, reference range changes, or modifications in specimen collection protocol and/or new specimen collection devices.

jun. 28, 2019

July 2019 Test Bulletin

New Medicare Cards: Medicare Beneficiary ID (MBI) System Restrictions -- ACL Laboratories Announces New Test Swabone™ Mycoplasma Genitalium by TMA -- (Test Order Code SWOMG) -- ACL Laboratories Discontinues In-House Testing for Test Order Codes: HIVGEN, HIVING, TOXPCR and PRVB19 -- ACL Testing Methodology Changes from Rapid Antigen/Culture Techniques to Rapid Molecular Testing ... Read more

may. 29, 2019

June 2019 Test Bulletin

Heparin Dependent Antibody (PF4IGG, PF4IGR & HDA) Sample Requirements Change -- New Syphilis Total Antibody Assay (Test Order Code SYPT) Read more

mar. 25, 2019

April 2019 Test Bulletin

Urine Erythrocyte (ERYT) Reference Range and Reporting Range Changes for Asymptomatic MicroHematuria (AMH) -- ACL Laboratories Discontinues In-house Testing for Test Order Codes: CY2C19, CYP2D6, HBVGT, TISSMSI -- ALT (Test Order Code GPT) Reference Range Update Read more

feb. 28, 2019

March 2019 Test Bulletin

ACL Laboratories Updates Cytogenetics Testing Forms -- ACL Laboratories Offers New Reportable HIV Integrase Drug for Test Order Code HIVING -- Inactivated Code with REF Code Read more

jan. 30, 2019

February 2019 Test Bulletin

ACL Laboratories Offers Comprehensive Drug Screen – Pain Management Profile 1 (Test Order Code QPNMG1) and deactivates Drug Abuse Panel – Drug Management (Test Order Code DMABUS) -- Pain Management Drug Panel (Test Order Code DRGPM2) -- Pain Management Drug Screen with Interpretation (Test Order Code DRUGPM) Read more